ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

ClinicalTrials.gov ID: NCT01510184

Public ClinicalTrials.gov record NCT01510184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 12:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Study identification

NCT ID
NCT01510184
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Enrollment
79 participants

Conditions and interventions

Interventions

  • In-111 Zevalin Drug
  • Rituximab Drug
  • Y-90-Zevalin Drug
  • Zevalin Drug

Drug

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 18, 2012
Primary completion
Oct 22, 2014
Completion
Oct 22, 2014
Last update posted
Dec 15, 2021

2012 – 2014

United States locations

U.S. sites
28
U.S. states
21
U.S. cities
27
Facility City State ZIP Site status
Cancer Treatment Services Arizona Casa Grande Arizona 85122
Sutter East Bay Hospitals Berkeley California 94704
City of Hope Duarte California 91010
Halifax Health Medical Center Daytona Beach Florida 32114
H. Lee Moffitt Cancer Center Tampa Florida 33612
Piedmont Hospital Cancer Center Atlanta Georgia 30318
St. Luke's Mountain States Tumor Institute (MSTI) Boise Idaho 83712
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
Rush University Medical Center Chicago Illinois 60612
Decatur Memorial Hospital Cancer Care Specialists of Central Illinois Decatur Illinois 62526
Illinois Cancer Specialists Niles Illinois 60714
Midwestern Regional Medical Center Zion Illinois 60099
University of Iowa Hospitals and Clinics Iowa City Iowa 52242
Norton Cancer Institute, Suburban Louisville Kentucky 40207
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
St. John Hospital and Medical Center Grosse Pointe Woods Michigan 48236
Oncology Research-Park Nicollet Institute Saint Louis Park Minnesota 55426
Saint Louis University St Louis Missouri 63110
Comprehensive Cancer Centers of Nevada Henderson Nevada 89044
Hackensack UMC / John Theurer Cancer Center Hackensack New Jersey 07601
Memorial Sloan-Kettering Cancer Center New York New York 10065
Adams Cancer center Gettysburg Pennsylvania 17325
York Cancer Center / Cancer Care Associates of York York Pennsylvania 17403
Saint Francis Hospital Greenville South Carolina 29601
Avera Hematology and Transplant Sioux Falls South Dakota 57105
Associates In Oncology and Hematology Chattanooga Tennessee 37421
The University of Texas M.D. Anderson Cancer Center Houston Texas 77030
Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01510184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 15, 2021 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01510184 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →